Antidepressants for depression in physically ill people (Q24236616)

6

0 references

author name string

Annabel Price

2

0 references

Alison Evans

3

0 references

Koravangattu Valsraj

4

0 references

Irene J Higginson

Cochrane Database of Systematic Reviews

5

0 references

publication date

17 March 2010

0 references

published in

0 references

cites work

The effects of dothiepin on subjects with rheumatoid arthritis and depression.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Fluoxetine in depressed patients on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

SSRIs in the treatment of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

A controlled trial of antidepressants in patients with Parkinson disease and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Sertraline treatment of major depression in patients with acute MI or unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Antidepressant pharmacotherapy of depression associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

The effect of low dose lofepramine in depressed elderly patients in general medical wards

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Structured group therapy and fluoxetine to treat depression in HIV-positive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Fluoxetine Versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Treatment of cognitive impairment after poststroke depression : a double-blind treatment trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Randomized trial of paroxetine in end-stage COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

The prevalence of comorbid depression in adults with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Psychological and pharmacological interventions for depression in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Functional impairment and co-occurring psychiatric disorders in medically hospitalized men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Depression following myocardial infarction. Impact on 6-month survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Association between unreported outcomes and effect size estimates in Cochrane meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Therapies for depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Interventions for treating depression after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Mental disorders among internal medical inpatients: prevalence, detection, and treatment status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Relative mortality from overdose of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Diagnostic groups and depressed mood as predictors of 22-month mortality in medical inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Depression in advanced disease: a systematic review Part 1. Prevalence and case finding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Management of depression in UK general practice in relation to scores on depression severity questionnaires: analysis of medical record data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Pharmacologic treatment of depression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Depression and increased mortality in diabetes: unexpected causes of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Depression, chronic diseases, and decrements in health: results from the World Health Surveys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Relationship of psychosocial factors to HIV disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Physical measures for treating depression in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

A systematic review of prevalence studies of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Prevalence of psychiatric disorders in medical inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Prevalence of depression in survivors of acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

Measurement of depression in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Placebo-controlled treatment trial of depression in elderly physically ill patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

A trial of imipramine (Tofranil) in depressed patients with chronic physical disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

The treatment of depression in patients with epilepsy. A double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Effect of desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Trazodone therapy of the post-stroke depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Nortriptyline treatment of post-stroke depression: a double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Psychiatric disorders in relation to medical illness among patients of a general medical out-patient clinic.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Evaluating psychiatric morbidity in a general hospital: a two-phase epidemiological survey

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Pessimism, age, and cancer mortality

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Effective low dose tricyclic antidepressant treatment for depressed geriatric rehabilitation patients. A double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

The effect of fluoxetine on anxiety and depression symptoms in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Fluoxetine in early poststroke depression: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Depression, perception of illness and mortality in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Depression, Introversion and Mortality following Stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Antidepressant pharmacotherapy and the treatment of depression in patients with severe traumatic brain injury: a controlled, prospective study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007503.PUB2

7 January 2021

10.1002/14651858.CD007503.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2386850

2386850

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference